JPRN-UMIN000010319已完成2 期
Phase II study of TS-1+Irinotecan+Bevacizumab as second-line treatment in patients with metastatic colorectal cancer refractory to fluoronated pyrimidine, oxaliplatin, and cetuximab therapy - JACCRO CC-07 study
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 70
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •(1)Synchronous multiple malignancy or metachronous multiple malignancy within 5 years disease free interval (2)Symptomatic brain metastases (3)Infectious disease (4)Interstitial lung disease or pulmonary fibrosis (5)Comorbidity or history of heart failure (6)History of thromboembolic events (7)History of hemoptysis (8)Sensory alteration or paresthesia interfering with function (9)Large quantity of pleural, abdominal or cardiac effusion (10)Severe comorbidity (renal failure, liver failure, hypertension, etc) (11)Prior radiotherapy for primary and metastases tumors (12)Men/women who are unwilling to avoid pregnancy. Women who are pregnant or breast feeding. Women with a positive pregnancy test (13)History of severe allergy (14)Surgical procedure or such as skin-open biopy, trauma surgery, or other more intensive surgeries within 4 weeks (15)Systemic administration of antiplatelet drug or NSAIDs (16)Diathesis of bleeding (history of hemoptysis, including cavitation and/or necrosis in lung metastasis confirmed by imaging), coagulopathy (17)Uncontrolled peptic ulcer (18)History of gastrointestinal perforation within 1 year (19)Untreated traumatic bone fracture (20)Require treatment of renal dysfunction (21)Doubting dihydropyrimidine dehydrogenase deficit (22) Uncontrolled diarrhea (23)History of organ recipient (24)Administration of atazanavir sulfate (25Administration of flucytosine (26)Jaundice (27) Ileus or bowel obstruction (28)Any other cases who are regarded as inadequate for study enrollment by investigators
研究者
相似试验
已完成
2 期
Phase II study of bevacizumab and irinotecan as second-line therapy in patients with metastatic colorectal cancer previously treated with fluoropyrimidine, oxaliplatin, and bevacizumabJPRN-UMIN000005228Tokyo Women's Medical University33
招募中
不适用
Phase 2 study of bevacizumab and irinotecan as second-line therapy in patients with advanced colorectal cancer previously treated with oxaliplatin and bavacizumabadvanced colorectal cancerJPRN-UMIN000007065Toyama Prefectural Central Hospital Department of Gastroenterology33
已完成
2 期
Phase II study of bevacizumab and irinotecan plus alternate-day S-1 as second-line therapy in patients with metastatic colorectal cancer.Metastatic colorectal cancer.JPRN-UMIN000008947Epidemiological and Clinical research Information Network (ECRIN)40
已完成
1 期
A phaseI/II study of irinotecan with bevacizumab as second line treatment of elderly patients with metastatic colorectal cancer.colorectal cancerJPRN-UMIN000009911Tsuchiura kyodo general hospital25
已完成
2 期
A phaseII study of irinotecan with bevacizumab as third line treatment for patients with metastatic colorectal cancer after failure to irinotecan who have progressed on bevacizumab with oxaliplatin-based chemotherapy in second line.colorectal cancerJPRN-UMIN000009910Tsuchiura kyodo general hospital25